Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)

Vito Chiantera, Polat Dursun, Vito Chiantera, Nasuh Utku Dogan, Selen Dogan, Achim Schneider

Risultato della ricerca: Article

3 Citazioni (Scopus)

Abstract

Ovarian cancer is the most lethal gynecological malignancy, with aggressive surgical debulking and adjuvant chemotherapy as the main treatment modalities. Optimal debulking during the primary surgery is significantly correlated with prolonged survival. As surgical techniques and chemotherapeutic agents improve, more patients with prolonged survival may face secondary and tertiary recurrences. The role of surgical debulking in secondary cytoreduction (SC) is not clearly defined and is based on retrospective series. The treatment of patients with primary or secondary recurrences generally consists of second-line chemotherapy, but may be performed on medically fit patients in certain circumstances. A limited number of studies concerning tertiary cytoreduction (TC) in cases of secondary recurrences have been published. In these studies, conventional prognostic factors for SC, including ascites, an advanced International Federation of Gynecology and Obstetrics (FIGO) stage and/or peritoneal carcinomatosis, did not apply to TC, but the post-operative residual tumor load was significant in determining the prognosis. A limited number of patients with completely-resectable tumors may have an opportunity for a maximal cytoreduction in these circumstances. TC appears to result in a favorable outcome and moderate complication rates. The surgery is an available option for patients with recurrence, in whom a complete tumor resection may be achieved
Lingua originaleEnglish
pagine (da-a)642-647
Numero di pagine6
RivistaOncology Letters
Volume6
Stato di pubblicazionePublished - 2013

Fingerprint

Ovarian Neoplasms
Recurrence
Neoplasms
Survival
Residual Neoplasm
Adjuvant Chemotherapy
Tumor Burden
Gynecology
Ascites
Obstetrics
Carcinoma
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo

Chiantera, V., Dursun, P., Chiantera, V., Dogan, N. U., Dogan, S., & Schneider, A. (2013). Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review). Oncology Letters, 6, 642-647.

Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review). / Chiantera, Vito; Dursun, Polat; Chiantera, Vito; Dogan, Nasuh Utku; Dogan, Selen; Schneider, Achim.

In: Oncology Letters, Vol. 6, 2013, pag. 642-647.

Risultato della ricerca: Article

Chiantera, V, Dursun, P, Chiantera, V, Dogan, NU, Dogan, S & Schneider, A 2013, 'Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)', Oncology Letters, vol. 6, pagg. 642-647.
Chiantera V, Dursun P, Chiantera V, Dogan NU, Dogan S, Schneider A. Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review). Oncology Letters. 2013;6:642-647.
Chiantera, Vito ; Dursun, Polat ; Chiantera, Vito ; Dogan, Nasuh Utku ; Dogan, Selen ; Schneider, Achim. / Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review). In: Oncology Letters. 2013 ; Vol. 6. pagg. 642-647.
@article{9ba6854ff4214dbea8761918d49ded8e,
title = "Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)",
abstract = "Ovarian cancer is the most lethal gynecological malignancy, with aggressive surgical debulking and adjuvant chemotherapy as the main treatment modalities. Optimal debulking during the primary surgery is significantly correlated with prolonged survival. As surgical techniques and chemotherapeutic agents improve, more patients with prolonged survival may face secondary and tertiary recurrences. The role of surgical debulking in secondary cytoreduction (SC) is not clearly defined and is based on retrospective series. The treatment of patients with primary or secondary recurrences generally consists of second-line chemotherapy, but may be performed on medically fit patients in certain circumstances. A limited number of studies concerning tertiary cytoreduction (TC) in cases of secondary recurrences have been published. In these studies, conventional prognostic factors for SC, including ascites, an advanced International Federation of Gynecology and Obstetrics (FIGO) stage and/or peritoneal carcinomatosis, did not apply to TC, but the post-operative residual tumor load was significant in determining the prognosis. A limited number of patients with completely-resectable tumors may have an opportunity for a maximal cytoreduction in these circumstances. TC appears to result in a favorable outcome and moderate complication rates. The surgery is an available option for patients with recurrence, in whom a complete tumor resection may be achieved",
author = "Vito Chiantera and Polat Dursun and Vito Chiantera and Dogan, {Nasuh Utku} and Selen Dogan and Achim Schneider",
year = "2013",
language = "English",
volume = "6",
pages = "642--647",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",

}

TY - JOUR

T1 - Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)

AU - Chiantera, Vito

AU - Dursun, Polat

AU - Chiantera, Vito

AU - Dogan, Nasuh Utku

AU - Dogan, Selen

AU - Schneider, Achim

PY - 2013

Y1 - 2013

N2 - Ovarian cancer is the most lethal gynecological malignancy, with aggressive surgical debulking and adjuvant chemotherapy as the main treatment modalities. Optimal debulking during the primary surgery is significantly correlated with prolonged survival. As surgical techniques and chemotherapeutic agents improve, more patients with prolonged survival may face secondary and tertiary recurrences. The role of surgical debulking in secondary cytoreduction (SC) is not clearly defined and is based on retrospective series. The treatment of patients with primary or secondary recurrences generally consists of second-line chemotherapy, but may be performed on medically fit patients in certain circumstances. A limited number of studies concerning tertiary cytoreduction (TC) in cases of secondary recurrences have been published. In these studies, conventional prognostic factors for SC, including ascites, an advanced International Federation of Gynecology and Obstetrics (FIGO) stage and/or peritoneal carcinomatosis, did not apply to TC, but the post-operative residual tumor load was significant in determining the prognosis. A limited number of patients with completely-resectable tumors may have an opportunity for a maximal cytoreduction in these circumstances. TC appears to result in a favorable outcome and moderate complication rates. The surgery is an available option for patients with recurrence, in whom a complete tumor resection may be achieved

AB - Ovarian cancer is the most lethal gynecological malignancy, with aggressive surgical debulking and adjuvant chemotherapy as the main treatment modalities. Optimal debulking during the primary surgery is significantly correlated with prolonged survival. As surgical techniques and chemotherapeutic agents improve, more patients with prolonged survival may face secondary and tertiary recurrences. The role of surgical debulking in secondary cytoreduction (SC) is not clearly defined and is based on retrospective series. The treatment of patients with primary or secondary recurrences generally consists of second-line chemotherapy, but may be performed on medically fit patients in certain circumstances. A limited number of studies concerning tertiary cytoreduction (TC) in cases of secondary recurrences have been published. In these studies, conventional prognostic factors for SC, including ascites, an advanced International Federation of Gynecology and Obstetrics (FIGO) stage and/or peritoneal carcinomatosis, did not apply to TC, but the post-operative residual tumor load was significant in determining the prognosis. A limited number of patients with completely-resectable tumors may have an opportunity for a maximal cytoreduction in these circumstances. TC appears to result in a favorable outcome and moderate complication rates. The surgery is an available option for patients with recurrence, in whom a complete tumor resection may be achieved

UR - http://hdl.handle.net/10447/179450

UR - http://www.spandidos-publications.com/serveFile/ol_6_3_642_PDF.pdf?type=article&article_id=ol_6_3_642&item=PDF

M3 - Article

VL - 6

SP - 642

EP - 647

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

ER -